Health economic evaluation of the 'DELIVER-CARE' study: a randomized controlled trial on delegation for chronic inflammatory diseases
In brief
Nurse-led chronic disease care had a 94% chance of cost-effectiveness
In a randomized trial of 602 patients with chronic inflammatory diseases, nurse-led consultations had a 94% probability of being cost-effective at a threshold of €50,000 per quality-adjusted life-year. Yet costs were not significantly lower and quality of life was similar to specialist care, so whether the model saves money in routine practice remains uncertain.
- Journal
- The European journal of health economics : HEPAC : health economics in prevention and care (Q1)
- Published
- 21 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Luisa V Licker, Tim Schikowski, Juliane Schiller, Franziska Püschner, Volker E Amelung, Dirk Meyer-Olson, et al.
- PMID
- 43064903
- DOI
- 10.1007/s10198-026-02015-1
Why clinicians should know about it
- Picked for Gastroenterology (top studies of the week, 22 November 2026): Randomized evaluation of delegated care for gastroenterology patients
Abstract
Given the increasing shortage of medical specialists in Germany, delegating selected physician tasks to nurses has been proposed to maintain care quality for patients with chronic inflammatory diseases (CID). This study evaluated the health economic impact of a nurse-led care (NLC) model, in which nurses conducted structured, delegated consultations, compared with standard specialist care, within the Deliver-Care randomized controlled trial. This trial, conducted between 2020 and 2023 at 56 specialist outpatient practices and hospital clinics, randomized 602 patients with rheumatological, gastroenterological, or dermatological CID to the intervention group (IG, n = 295) or control group (CG, n = 307). Healthcare costs (FIMA questionnaire) were assessed at baseline and 12 months, and EQ-5D-based utility values at baseline, 6 and 12 months. Analyses followed the intention-to-treat principle, with missing data handled using multiple imputation. Group differences in costs were assessed using generalized estimating equations, and cost-effectiveness was evaluated using bootstrapping (5,000 replications) and cost-effectiveness acceptability curves. Mean total costs at 12 months were €12,061 (IG) versus €13,601 (CG), a non-significant difference (p = 0.286), with no significant group-by-time interaction. QALY gains were comparable between groups (IG: 0.80; CG: 0.78). The intervention was dominant in 87.2% of bootstrap replications, with a 94% probability of cost-effectiveness at a willingness-to-pay threshold of €50,000 per QALY. While no significant reduction in healthcare costs or improvement in quality of life were observed, the NLC model showed a high probability of cost-effectiveness, suggesting it may serve as a cost-neutral to potentially cost-saving alternative to standard care.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.